Opendata, web and dolomites


Reliable urinary test for the diagnosis of prostate cancer

Total Cost €


EC-Contrib. €






Project "PROSTATOR" data sheet

The following table provides information about the project.


Organization address
address: rue d'Ulm 26
city: PARIS
postcode: 75231

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2021-07-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT CURIE FR (PARIS) coordinator 150˙000.00


 Project objective

Reliable urinary test for the diagnosis of prostate cancer Prostate cancer is a life threatening disease which affects about 400,000 males and causes 92,000 deaths per year in Europe. Among suspected cancer patients who undergo a prostate biopsy, only 45% really have a cancer. However, this diagnostic procedure is associated with discomfort, anxiety, bleeding, and the potential for serious infections requiring hospitalization. It is also very expensive. None of the tests available today offer an alternative which avoids unnecessary biopsies. To solve this problem we propose to validate a urinary, non-invasive, rapid and robust diagnostic test that we call PROSTATOR, for the early detection of prostate cancer without unnecessary biopsies. PROSTATOR quantifies three new prostate cancer specific biomarkers that we identified using our ERC Consolidator Grant. We show that, contrary to the biomarkers quantified by commercialized urinary tests for prostate cancer, our three new biomarkers were detected in all grades of tumours. Only cancer patients detected by our test will have a biopsy to determine the type and the grade of the prostate tumour but unnecessary biopsies will be avoided when the test is negative. Other advantages of our novel test: it can be performed from the first visit to the urologist, collecting the urine after prostatic massage and sending it to a laboratory that will give the diagnosis within 4 days. With this grant, we want to validate our first results on a large number of urines (900). We have established collaborations with Henri-Mondor and Foch hospitals to collect the urines and with the Genomic Platform of Institut Curie to quantify our biomarkers. We started discussions with tech transfer office of the Institut Curie to discuss the opportunity to license PROSTATOR to pharmaceutical companies that already confirmed their interest of our product, or create a start-up.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROSTATOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROSTATOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  

Photopharm (2020)

Photopharmacology: From Academia toward the Clinic.

Read More  

DimorphicCircuits (2019)

Elucidating the development of sexually-dimorphic circuits: from molecular mechanisms to synapses and behavior

Read More